Surrozen, Inc. (SRZN)
25.48
-0.27
(-1.05%)
USD |
NASDAQ |
Oct 23, 16:00
25.40
-0.08
(-0.31%)
After-Hours: 20:00
Surrozen Net Income (Quarterly) : 32.04M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 32.04M |
| March 31, 2026 | -127.50M |
| December 31, 2025 | -183.16M |
| September 30, 2025 | -71.64M |
| June 30, 2025 | 21.81M |
| March 31, 2025 | -26.97M |
| December 31, 2024 | -28.04M |
| September 30, 2024 | -1.434M |
| June 30, 2024 | -25.26M |
| March 31, 2024 | -8.83M |
| December 31, 2023 | -8.913M |
| September 30, 2023 | -10.44M |
| Date | Value |
|---|---|
| June 30, 2023 | -9.387M |
| March 31, 2023 | -14.30M |
| December 31, 2022 | -0.775M |
| September 30, 2022 | -13.36M |
| June 30, 2022 | -13.92M |
| March 31, 2022 | -7.947M |
| December 31, 2021 | -14.95M |
| September 30, 2021 | -14.02M |
| June 30, 2021 | -12.65M |
| March 31, 2021 | -13.02M |
| December 31, 2020 | -10.83M |
| September 30, 2020 | -8.635M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 5.00M |
| Total Expenses (Quarterly) | -27.04M |
| EPS Diluted (Quarterly) | -0.4059 |
| Enterprise Value | 203.77M |
| Gross Profit Margin (Quarterly) | 98.98% |
| Earnings Yield | -173.8% |
| Normalized Earnings Yield | -97.41 |